Does Biogen's Recent Win Make It a Must-Buy Stock?
Shares of Biogen (NASDAQ: BIIB) soared late last month after the company again received positive results around one of its Alzheimer's treatments. It wasn't Aduhelm this time, but a new promising treatment called lecanemab, which the company is hoping can slow down the disease.
On the news, the stock surged to heights it hasn't been at since November of last year. Does the price jump signal a turnaround for Biogen, and is now the time to buy shares of the healthcare company before its value rises even further?
On Sept. 27, Biogen released results from a phase 3 trial involving nearly 1,800 people who tested lecanemab's effectiveness in treating Alzheimer's. Lecanemab met the primary endpoint of the trial, slowing the disease's progression by 27% when compared to a placebo.
Source Fool.com
